ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The gene-sequencing instrument firm Illumina will pay roughly $8 billion in cash and stock to buy Grail, a company working on technology for early detection of cancer. Grail was spun off from Illumina in 2016 and over the next 4 years raised more than $2 billion to develop a “liquid biopsy,” wherein cancer is detected at an early stage by sequencing DNA fractions from a simple blood sample. The diagnostic firm expects to launch Galleri, a multicancer test, in 2021. Clinical studies show a previous version of the test could spot 50 types of cancer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter